tezepelumab治疗重症未控制哮喘2年临床应答与缓解
NAVIGATOR和DESTINATION研究评估tezepelumab治疗重症未控制哮喘的临床应答和缓解。52周内完全临床应答率tezepelumab组46% vs 安慰剂组24%(OR 2.83, 95%CI 2.10-3.82),治疗中临床缓解率28.5% vs 21.9%(OR 1.44, 95%CI 0.95-2.19)。
要点
- tezepelumab组52周完全临床应答率显著高于安慰剂组(46% vs 24%)
- 52周治疗中临床缓解率两组差异未达统计学意义(OR 1.44, 95%CI 0.95-2.19)
- 达到缓解者基线肺功能更好、炎症标志物更低且前一年急性发作更少
核心结论
- tezepelumab治疗与重症未控制哮喘患者获得完全临床应答和治疗中临床缓解的可能性增加相关。
- 完全临床应答和临床缓解均为临床重要结局,但可能由不同患者特征驱动。
研究设计与样本
- NAVIGATOR(NCT03347279)和DESTINATION(NCT03706079)为3期随机双盲安慰剂对照研究,DESTINATION为NAVIGATOR的延伸研究。
主要发现
- 第0-52周完全临床应答率:tezepelumab组46% vs 安慰剂组24%(OR 2.83, 95%CI 2.10-3.82)。
- 第0-52周治疗中临床缓解率:tezepelumab组28.5% vs 安慰剂组21.9%(OR 1.44, 95%CI 0.95-2.19)。
- 第>52-104周治疗中临床缓解率:tezepelumab组33.5% vs 安慰剂组26.7%(OR 1.44, 95%CI 0.97-2.14)。
- 第52周达到治疗中临床缓解者较达到完全临床应答者基线肺功能更好、炎症生物标志物水平更低且研究前12个月急性发作更少。
关键数值与推荐
- 完全临床应答定义:较前一年急性发作减少≥50%,且支气管舒张前FEV1改善≥100 mL或≥5%,且ACQ-6评分改善≥0.5,且医生评估哮喘改善。
- 治疗中临床缓解定义:ACQ-6总分≤1.5,肺功能稳定(支气管舒张前FEV1>基线95%),且评估期间无急性发作或口服糖皮质激素使用。
临床怎么用
- tezepelumab可用于重症未控制哮喘,以提高完全临床应答和治疗中临床缓解的可能性。
- 评估临床缓解时需综合考虑ACQ-6评分、肺功能稳定性和急性发作/口服激素使用情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In asthma, clinical response is characterised by disease improvement with treatment, whereas clinical remission is characterised by long-term disease stabilisation with or without ongoing treatment. The proportions of patients receiving tezepelumab who responded to treatment and who achieved on-treatment clinical remission were assessed in the NAVIGATOR (ClinicalTrials.gov identifier NCT03347279) and DESTINATION (ClinicalTrials.gov identifier NCT03706079) studies of severe, uncontrolled asthma. METHODS: NAVIGATOR and DESTINATION were phase 3, randomised, double-blind, placebo-controlled studies; DESTINATION was an extension of NAVIGATOR. Complete clinical response was defined as achieving all of the following: ≥50% reduction in exacerbations versus the previous year, improvements in pre-bronchodilator (BD) forced expiratory volume in 1 s (FEV1) of ≥100 mL or ≥5%, improvements in Asthma Control Questionnaire (ACQ)-6 score of ≥0.5 and physician's assessment of asthma improvement. On-treatment clinical remission was defined as an ACQ-6 total score ≤1.5, stable lung function (pre-BD FEV1 >95% of baseline) and no exacerbations or use of oral corticosteroids during the time periods assessed. RESULTS: Higher proportions of tezepelumab than placebo recipients achieved complete clinical response over weeks 0-52 (46% versus 24%; OR 2.83, 95% CI 2.10-3.82) and on-treatment clinical remission over weeks 0-52 (28.5% versus 21.9%; OR 1.44, 95% CI 0.95-2.19) and weeks >52-104 (33.5% versus 26.7%; OR 1.44, 95% CI 0.97-2.14). Tezepelumab recipients who achieved on-treatment clinical remission versus complete clinical response at week 52 had better preserved lung function and lower inflammatory biomarker levels at baseline, and fewer exacerbations in the 12 months before the study. CONCLUSIONS: Among patients with severe, uncontrolled asthma, tezepelumab treatment was associated with an increased likelihood of achieving complete clinical response and on-treatment clinical remission compared with placebo. Both are clinically important outcomes, but may be driven by different patient characteristics.
引用
- Wechsler ME, Brusselle G, Virchow JC, et al. Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies. Eur Respir J. 2024. PMID: 39326921. doi:10.1183/13993003.00316-2024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。